Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

78.97
+1.351.74%
Post-market: 79.000.0300+0.04%19:57 EDT
Volume:9.86M
Turnover:778.72M
Market Cap:198.30B
PE:11.48
High:79.49
Open:78.30
Low:78.21
Close:77.62
Loading ...

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
20 May

Merck Says First Patient Dosed in Phase 3 Study of Ifinatamab Deruxtecan

MT Newswires Live
·
19 May

Ideate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

THOMSON REUTERS
·
19 May

Mixed options sentiment in Merck (MRK), with shares up $1.25 (+1.68%) near $76.06

TIPRANKS
·
17 May

Merck & Co. Inc. to Present New Clinical and Outcomes Research Data on Pulmonary Arterial Hypertension at the American Thoracic Society's International Conference

Reuters
·
16 May

1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid

Motley Fool
·
16 May

Stock Track | Merck Stock Soars 5% as Trump's Drug Pricing Order Sparks Investor Optimism

Stock Track
·
16 May

BRIEF-UK's MHRA Approves Vaccine To Protect Against Pneumococcal Infections Like Pneumonia & Meningitis

Reuters
·
16 May

UK's Mhra: Approved Capvaxive for People Aged 18 Years & Older to Help Protect Against Pneumococcal Infections

THOMSON REUTERS
·
16 May

UK's Mhra: Approves Vaccine to Protect Against Pneumococcal Infections Such as Pneumonia and Meningitis - Website

THOMSON REUTERS
·
16 May

Immutep Says Efti Triple Combination Improves Response Rate in Non-Small Cell Lung Cancer

MT Newswires Live
·
15 May

BRIEF-Merck Announces Phase 3 Keynote-B96 Trial Met Primary Endpoint Of Progression-Free Survival (Pfs) In Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed Pd-L1 And In All Comers

Reuters
·
15 May

Merck Says Late-Stage Ovarian Cancer Trial for Keytruda Meets Primary Endpoint

MT Newswires Live
·
15 May

Merck Announces Successful Phase 3 Trial Results for KEYTRUDA in Treating Platinum-Resistant Ovarian Cancer

Reuters
·
15 May

Merck & Co Inc - Study Meets Secondary Endpoint of Overall Survival

THOMSON REUTERS
·
15 May

Merck Announces Phase 3 Keynote-B96 Trial Met Primary Endpoint of Progression-Free Survival (Pfs) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed Pd-L1 and in All Comers

THOMSON REUTERS
·
15 May

Merck Gets FDA Approval for Tumor Treatment Welireg

Dow Jones
·
15 May

Merck Gets FDA Approval for Welireg to Treat Rare Tumors

MT Newswires Live
·
15 May

Merck’s Welireg for PPGL approved by FDA

TIPRANKS
·
15 May

BRIEF-FDA Approves Merck’S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL)

Reuters
·
15 May